Abacavir Use and Risk of Acute Myocardial Infarction and Cerebrovascular Events in the Highly Active Antiretroviral Therapy Era

Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial

(2010) Allison Martin et al.   AIDS

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

(2010) Esteban Martínez et al.   AIDS

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

(2010) Marisa Tungsiripat et al.   AIDS

Kidney function and the risk of cardiovascular events in HIV-1-infected patients

(2010) Elizabeth George et al.   AIDS

Association Between Kidney Function and Albuminuria With Cardiovascular Events in HIV-Infected Persons

(2010) Andy I. Choi et al.   CIRCULATION

Hepatitis C Virus Infection and Increased Risk of Cerebrovascular Disease

(2010) Mei-Hsuan Lee et al.   STROKE

Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir

(2010) Eefje Jong et al.   AIDS Research and Therapy

Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study

(2009) Carl Grunfeld et al.   AIDS

Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients

(2009) Priscilla Y Hsue et al.   AIDS

Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial

(2009) Allison Martin et al.   CLINICAL INFECTIOUS DISEASES

Relationship between Inflammatory Markers, Endothelial Activation Markers, and Carotid Intima‐Media Thickness in HIV‐Infected Patients Receiving Antiretroviral Therapy

(2009) Allison C. Ross et al.   CLINICAL INFECTIOUS DISEASES

Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study

(2009) N Obel et al.   HIV MEDICINE

Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The “Mortalité 2000 and 2005” Surveys (ANRS EN19 and Mortavic)

(2009) Charlotte Lewden et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects

(2009) Cindy H Brothers et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study

(2009) Signe Westring Worm et al.   JOURNAL OF INFECTIOUS DISEASES

Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

(2009) Paul E. Sax et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

(2008)   AIDS

Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy

(2008) Judith S. Currier et al.   CIRCULATION

Endothelial Activation Markers Are Linked to HIV Status and Are Independent of Antiretroviral Therapy and Lipoatrophy

(2008) Allison C Ross et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Abacavir and increased risk of myocardial infarction

(2008) Frank A Post et al.   LANCET

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

(2008)   LANCET